معرفی
Joaquim Bellmunt serves as Associate Professor at Harvard Medical School and Director of the Bladder Cancer Center at Dana-Farber Cancer Institute's Genitourinary Oncology Program. His clinical expertise encompasses urological cancers including bladder, prostate, and kidney malignancies. Dr. Bellmunt has pioneered immunotherapy treatments for bladder cancer, leading pivotal clinical trials for FDA-approved agents such as atezolizumab and pembrolizumab.
His research focuses on developing innovative therapeutic approaches and identifying prognostic biomarkers in genitourinary cancers. He has led landmark studies establishing new standards of care, including research demonstrating survival benefits of immunotherapy over chemotherapy in advanced bladder cancer. Dr. Bellmunt actively investigates adjuvant therapies and circulating tumor DNA applications for minimal residual disease monitoring.
